Contract laboratories aiming to deliver precise and human-relevant data can now utilize CN Bio’s PhysioMimix® Bioavailability Assay Kit: Human 18. This groundbreaking kit combines CN Bio’s Liver-on-a-Chip model with Altis Biosystems’ RepliGut® Jejunum model, forming a dual-organ system that replicates human bioavailability processes.
Key Benefits for Contract Laboratories
The PhysioMimix Bioavailability Assay Kit is designed to meet the unique demands of contract testing labs:
- Predictive Human Data: Accurately simulates drug absorption, metabolism, and clearance.
- Flexible Dosing Models: Supports both intravenous and oral dosing to expand testing capabilities.
- High-Throughput Testing: Generates up to 18 replicates, optimizing client project turnaround.
- Client-Ready Validation: Streamlines adoption with pre-validated, easy-to-use assay components.
According to Dr. Ben Scruggs, CEO of Altis Biosystems, the kit allows labs to access the power of organ-on-a-chip technologies, offering clients superior bioavailability data while minimizing reliance on animal studies.
This innovation enables contract laboratories to differentiate themselves in the competitive landscape of preclinical drug testing by delivering more predictive and reliable human data.
This article is an AI generated summary of a published press release: “CN Bio launches PhysioMimix Bioavailability assay kit: Human 18“
